Related Experiment Video

Updated: May 13, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Mechanisms of resistance to anti-angiogenesis therapies

Sandy Giuliano1, Gilles Pagès

  • 1University of Nice Sophia Antipolis, Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS Unit 7284/INSERM Unit 1081, 33 Avenue de Valombrose, 06189 Nice, France.

Biochimie
|March 20, 2013
PubMed

Insights

Anti-angiogenic cancer therapies targeting VEGF show promise in extending progression-free survival but often lead to resistance. Understanding resistance mechanisms is key to improving overall survival in cancer patients.

Area of Science:

  • Oncology
  • Cancer Biology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth, progression, and metastasis.
  • Inhibiting angiogenesis is a key strategy in cancer treatment, leading to the development of anti-angiogenic drugs.
  • Bevacizumab, targeting Vascular Endothelial Growth Factor (VEGF), was the first FDA-approved anti-angiogenic drug for various metastatic cancers.

Purpose of the Study:

  • To review current anti-angiogenic treatments for cancer.
  • To discuss the efficacy of these treatments, including progression-free and overall survival benefits.
  • To explore the mechanisms of primary and acquired resistance to anti-angiogenic therapies.

Main Methods:

  • Literature review of studies on angiogenesis inhibitors in cancer treatment.
  • Analysis of clinical trial data regarding efficacy and survival outcomes.
  • Examination of identified mechanisms of resistance to anti-angiogenic drugs.

Main Results:

  • Anti-angiogenic drugs, like bevacizumab, have shown statistically significant increases in progression-free survival for metastatic cancers.
  • While overall survival benefits are often modest, some patients experience a substantial increase in lifespan.
  • Acquired resistance is a common challenge, leading to inevitable tumor relapse.

Conclusions:

  • Anti-angiogenic therapies represent an important advancement in cancer treatment, particularly for extending progression-free survival.
  • Overcoming resistance mechanisms is critical for improving long-term patient outcomes and overall survival.
  • Further research into resistance pathways is essential for developing more effective combination therapies.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...